Cited by 301Hormonal Regulation and HypertensionRenin-Angiotensin System StudiesBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Characterization of Resistant Hypertension<subtitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subtitle>

Open access

Gaddam, Krishna K.·2008·Archives of Internal Medicine

DOI 10.1001/archinte.168.11.1159PMC PMC2748247

Open this paper in CoChat — free account

Abstract

BACKGROUND: Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage. METHODS: We evaluated the characteristics of 279 consecutive patients with resistant hypertension (uncontrolled despite the use of 3 antihypertensive agents) and 53 control subjects (with normotension or hypertension controlled by using <or=2 antihypertensive medications). Participants were prospectively examined for plasma aldosterone concentration, plasma renin activity, aldosterone to renin ratio, brain-type natriuretic peptide, atrial natriuretic peptide, and 24-hour urinary aldosterone (UAldo), cortisol, sodium, and potassium values while adhering to a routine diet. RESULTS: Plasma aldosterone (P < .001), aldosterone to renin ratio (P < .001), 24-hour UAldo (P = .02), brain-type natriuretic peptide (P = .007), and atrial natriuretic peptide (P = .001) values were higher and plasma renin activity (P = .02) and serum potassium (P < .001) values were lower in patients with resistant hypertension vs controls. Of patients with resistant hypertension, men had significantly higher plasma aldosterone (P = .003), aldosterone to renin ratio (P = .02), 24-hour UAldo (P < .001), and urinary cortisol (P < .001) values than women. In univariate linear regression analysis, body mass index (P = .01), serum potassium (P < .001), urinary cortisol (P < .001), urinary sodium (P = .02), and urinary potassium (P < .001) values were correlated with 24-hour UAldo levels. Serum potassium (P = .001), urinary potassium (P < .001), and urinary sodium (P = .03) levels were predictors of 24-hour UAldo levels in multivariate modeling. CONCLUSIONS: Aldosterone levels are higher and there is evidence of intravascular volume expansion (higher brain-type and atrial natriuretic peptide levels) in patients with resistant hypertension vs controls. These differences are most pronounced in men. A significant correlation between 24-hour urinary aldosterone levels and cortisol excretion suggests that a common stimulus, such as corticotropin, may underlie the aldosterone excess in patients with resistant hypertension.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archinte.168.11.1159

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000
Hajjar, I. M. (2003) · JAMA · doi:10.1001/jama.290.2.199 · Cited by 2,399
A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease
Pepine, C. J., Handberg, E. M., Cooper‐DeHoff, R. M., Marks, R. G., Kowey, P. R., Messerli, F. H., Mancia, G., Cangiano, J. L., García-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,278
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B., & Weissmann, P. (2002) · Hypertension · doi:10.1161/01.hyp.0000040261.30455.b6 · Cited by 763
Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial
Black, H. R. (2003) · JAMA · doi:10.1001/jama.289.16.2073 · Cited by 741
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
Chapman, N., Dobson, J., Wilson, S. L., Dahlöf, B., Sever, P., Wedel, H., & Poulter, N. R. (2007) · Hypertension · doi:10.1161/01.hyp.0000259805.18468.8c · Cited by 630
Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons
Vasan, R. S., Evans, J. C., Larson, M. G., Wilson, P. W. F., Meigs, J. B., Rifai, N., Benjamin, E. J., & Levy, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033263 · Cited by 573
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 500

Show all 32 references

Research works printed but not linked: 1

[19]Gomez-Sanchez CE. Adrenal steroid synthesis and regulation. In: Izzo JL, Black HR, editors. Hypertension primer. Liipincott Williams & Wilkins; Philadelphia: 2003. [Google Scholar]

Sorted by citations

2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Gomes, M. A. M., Brandão, A. A., Feitosa, A. D. M., Machado, C. A., Poli‐de‐Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,389
Prevalence of Resistant Hypertension in the United States, 2003–2008
Persell, S. D. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.170308 · Cited by 761
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K. A., Cloutier, L., Gelfer, M., Lamarre-Cliché, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 690
Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension: Results From a Randomized Trial
Pimenta, E., Gaddam, K. K., Oparil, S., Aban, I., Husain, S., Dell'Italia, L. J., & Calhoun, D. A. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131235 · Cited by 531
Self-citation
Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea
Witkowski, A., Prejbisz, A., Florczak, E., Kądziela, J., Śliwiński, P., Bieleń, P., Michałowska, I., Kabat, M., Warchoł, E., Januszewicz, M., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173799 · Cited by 460
Management of High Blood Pressure in Blacks
Flack, J. M., Sica, D. A., Bakris, G. L., Brown, A. L., Ferdinand, K. C., Grimm, R. H., Hall, W. D., Jones, W. E., Kountz, D. S., Lea, J. P., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.152892 · Cited by 450
2013 ESH/ESC Guidelines for the management of arterial hypertension
Mancia, G., Fagard, R. H., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T. C., Cífková, R., Backer, G. D., Dominiczak, A. F., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.812549 · Cited by 430
Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report
Gaddam, K., Pimenta, E., Thomas, S. J., Cofield, S. S., Oparil, S., Harding, S. M., & Calhoun, D. A. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2009.96 · Cited by 289
Self-citation
2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension
Lee, H., Shin, J., Kim, G., Park, S., Ihm, S., Kim, H. C., Kim, K., Kim, J. H., Lee, J. H., Park, J., et al. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0124-x · Cited by 274
Nocturnal blood pressure and cardiovascular disease: a review of recent advances
Yano, Y., & Kario, K. (2012) · Hypertension Research · doi:10.1038/hr.2012.26 · Cited by 227
Prevalence of Apparent Treatment-Resistant Hypertension in the United States
Carey, R. M., Sakhuja, S., Calhoun, D. A., Whelton, P. K., & Muntner, P. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12191 · Cited by 222
Treatment of Resistant and Refractory Hypertension
Acelajado, M. C., Hughes, Z. H., Oparil, S., & Calhoun, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.118.312156 · Cited by 226
Refractory Hypertension: Definition, Prevalence, and Patient Characteristics
Acelajado, M. C., Pisoni, R., Dudenbostel, T., Dell’Italia, L. J., Cartmill, F., Zhang, B., Cofield, S. S., Oparil, S., & Calhoun, D. A. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00556.x · Cited by 200
Severity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension
Gonzaga, C. C., Gaddam, K. K., Ahmed, M. I., Pimenta, E., Thomas, S. J., Harding, S. M., Oparil, S., Cofield, S. S., & Calhoun, D. A. (2010) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27878 · Cited by 188
Self-citation
Aldosterone and arterial hypertension
Tomaschitz, A., Pilz, S., Ritz, E., Obermayer-Pietsch, B. M., & Pieber, T. R. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.263 · Cited by 155
Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension
Whaley‐Connell, A. T., Johnson, M. S., & Sowers, J. R. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.12.004 · Cited by 155
Resistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism
Gaddam, K. K., Corros, C., Pimenta, E., Ahmed, M. I., Denney, T. S., Aban, I., Inusah, S., Gupta, H., Lloyd, S. G., Oparil, S., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.141531 · Cited by 149
Self-citation
Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous System
Tsioufis, C. P., Kordalis, A., Flessas, D., Anastasopoulos, I., Tsiachris, D., Papademetriou, V., & Stefanadis, C. (2011) · International Journal of Hypertension · doi:10.4061/2011/642416 · Cited by 140
Refractory Hypertension
Dudenbostel, T., Acelajado, M. C., Pisoni, R., Li, P., Oparil, S., & Calhoun, D. A. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05449 · Cited by 138
Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension
Kasai, T., Bradley, T. D., Friedman, O., & Logan, A. G. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000047 · Cited by 127
Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes
Oliveras, A., & Sierra, À. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.77 · Cited by 116
Hypertension and obstructive sleep apnea
Cai, A., Wang, L., & Zhou, Y. (2016) · Hypertension Research · doi:10.1038/hr.2016.11 · Cited by 112
Hyperaldosteronism as a Common Cause of Resistant Hypertension
Calhoun, D. A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-042711-135929 · Cited by 108
Aldosterone synthase inhibition in humans
Azizi, M., Amar, L., & Ménard, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs388 · Cited by 104
Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea
Yang, L., Zhang, H., Cai, M., Zou, Y., Jiang, X., Song, L., Liang, E., Bian, J., Wu, H., & Hui, R. (2016) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1131290 · Cited by 99
Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents
Tamargo, J. L., Segura, J., & Ruilope, L. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.879117 · Cited by 100
Refractory Hypertension
Dudenbostel, T., Siddiqui, M., Oparil, S., & Calhoun, D. A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.06587 · Cited by 78
The Role of Aldosteronism in Causing Obesity-Related Cardiovascular Risk
Calhoun, D. A., & Sharma, K. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.001 · Cited by 74
Management of hypertension in chronic kidney disease
Townsend, R. R., & Taler, S. J. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.114 · Cited by 71
Recognition and Management of Resistant Hypertension
Braam, B. G., Taler, S. J., Rahman, M., Fillaus, J. A., Greco, B., Forman, J. P., Reisin, E., Cohen, D. L., Saklayen, M. G., & Hedayati, S. S. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06180616 · Cited by 73
Resistant Hypertension, Secondary Hypertension, and Hypertensive Crises: Diagnostic Evaluation and Treatment
Acelajado, M. C., & Calhoun, D. A. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.07.002 · Cited by 70
The Growing Epidemic of Hypertension Among Children and Adolescents: A Challenging Road Ahead
Assadi, F. K. (2012) · Pediatric Cardiology · doi:10.1007/s00246-012-0333-5 · Cited by 63
Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone
Ori, Y., Chagnac, A., Korzets, A., Zingerman, B. V., Herman‐Edelstein, M., Bergman, M., Gafter, U., & Salman, H. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs587 · Cited by 62
A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea
Lloberes, P., Sampol, G., Espinel, E., Segarra-Medrano, A., Ramón, M. A., Romero, O., Ferrer, R., Martínez‐García, M. Á., & Tovar, J.-L. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000238 · Cited by 60
Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms
Bovée, D. M., Cuevas, C. A., Zietse, R., Danser, A. H. J., Colafella, K. M. M., & Hoorn, E. J. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00407.2020 · Cited by 61
Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials
Wang, C., Xiong, B., & Huang, J. (2016) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2016.02.016 · Cited by 58
Resistant Hypertension and Aldosterone: An Update
Clark, D., Ahmed, M. I., & Calhoun, D. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.010 · Cited by 54
Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome
Stiefel, P., Vallejo‐Vaz, A. J., Morillo, J. S. G., & Villar, J. (2011) · International Journal of Hypertension · doi:10.4061/2011/685238 · Cited by 56
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight
Bioletto, F., Bollati, M., Lopez, C., Arata, S., Procopio, M., Ponzetto, F., Ghigo, E., Maccario, M., & Parasiliti‐Caprino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094803 · Cited by 55
Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects
Toering, T. J., Gant, C. M., Visser, F. W., van der Graaf, A. M., Laverman, G. D., Danser, A. H. J., Faas, M. M., Navis, G. J., & Lely, A. T. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00109.2017 · Cited by 52
Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension
Dudenbostel, T., & Calhoun, D. A. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpw105 · Cited by 51
Renal denervation for the treatment of resistant hypertension: review and clinical perspective
Iliescu, R., Lohmeier, T. E., Tudorancea, I., Laffin, L., & Bakris, G. L. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00246.2015 · Cited by 50
Salt, the renin–angiotensin–aldosterone system and resistant hypertension
Shimosawa, T. (2013) · Hypertension Research · doi:10.1038/hr.2013.69 · Cited by 50
An Update on Refractory Hypertension
Matanes, F., Khan, B., Siddiqui, M., Dudenbostel, T., Calhoun, D. A., & Oparil, S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01185-6 · Cited by 49
Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES)
Kaczmarski, K., Sozio, S. M., Chen, J., Sang, Y., & Shafi, T. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1315-0 · Cited by 52
Aldosterone and cardiovascular disease
Carey, R. M. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283390fa4 · Cited by 48
Interaction of Aldosterone and Extracellular Volume in the Pathogenesis of Obesity-Associated Kidney Disease: A Narrative Review
Bomback, A. S., & Klemmer, P. J. (2009) · American Journal of Nephrology · doi:10.1159/000209744 · Cited by 48
Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic
Modolo, R., de Faria, A. P., Sabbatini, A. R., Barbaro, N. R., Ritter, A. M. V., & Moreno, H. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.03.005 · Cited by 50
Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift
White, L. H., Bradley, T. D., & Logan, A. G. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.94 · Cited by 50
Endothelial dysfunction in hypertension: The role of arginase
Danielle, L. M. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/199 · Cited by 48
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?
Manolis, A. S., Manolis, T. A., Melita, H., & Manolis, A. S. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0924-0 · Cited by 48
Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy
Bomback, A. S., Rekhtman, Y., Klemmer, P. J., Canetta, P. A., Radhakrishnan, J., & Appel, G. B. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.07.003 · Cited by 46
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Sidharta, P. N., Melchior, M., Kankam, M. K., & Dingemanse, J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s199051 · Cited by 48
Resistant Hypertension: Mechanisms and Treatment
Hwang, A. Y., Dietrich, E. A., Pepine, C. J., & Smith, S. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0754-x · Cited by 47
Adipokines: Novel Players in Resistant Hypertension
de Faria, A. P., Modolo, R., Fontana, V., & Moreno, H. (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12399 · Cited by 44
Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure
Siddiqui, M., Dudenbostel, T., & Calhoun, D. A. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.06.033 · Cited by 44
Adverse Cardiovascular Outcomes of Corticosteroid Excess
Pimenta, E., Wolley, M. J., & Stowasser, M. (2012) · Endocrinology · doi:10.1210/en.2012-1573 · Cited by 43
Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?
Prejbisz, A., Kołodziejczyk‐Kruk, S., Lenders, J. W. M., & Januszewicz, A. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-122887 · Cited by 43
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
Azizi, M., Brown, J. M., Dwyer, J. P., Flack, J. M., Jones, E. S. W., Kurlyandskaya, R., Li, H., Birve, F., Lihn, A. S., Perl, S., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02549-8 · Cited by 42
Characterization and treatment of resistant hypertension
Pisoni, R., Ahmed, M. I., & Calhoun, D. A. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0059-z · Cited by 42
Benefits of continuous positive airway pressure on blood pressure in patients with hypertension and obstructive sleep apnea: a meta-analysis
Shang, W., Zhang, Y., Liu, L., Chen, F., Wang, G., & Han, D. H. (2022) · Hypertension Research · doi:10.1038/s41440-022-00954-9 · Cited by 44
Burden of Resistant Hypertension in Hypertensive Patients with Non-Dialysis Chronic Kidney Disease
Nicola, L. D., Borrelli, S., Gabbai, F. B., Chiodini, P., Zamboli, P., Iodice, C., Vitiello, S., Conte, G., & Minutolo, R. (2011) · Kidney & Blood Pressure Research · doi:10.1159/000322923 · Cited by 41
Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism
Indra, T., Holaj, R., Štrauch, B., Rosa, J., Petrák, O., Krátká, Z., & Widimsky, J., Jr. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314549220 · Cited by 42
Medical symptoms and conditions in autistic women
Simantov, T., Pohl, A. L., Tsompanidis, A., Weir, E. M., Lombardo, M. V., Ruigrok, A. N. V., Smith, P. L., Allison, C. L., Baron‐Cohen, S., & Uzefovsky, F. (2021) · Autism · doi:10.1177/13623613211022091 · Cited by 43
Aldosterone Excess or Escape: Treating Resistant Hypertension
Girioli, S. U., de Souza, L. A., Yugar‐Toledo, J. C., Martins, L. C., Ferreira‐Melo, S. E., Coelho, O. R., Sierra, C., Coca, A., Pimenta, E., & Moreno, H. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00110.x · Cited by 40
Role of the Kidneys in Resistant Hypertension
Khawaja, Z. Q., & Wilcox, C. S. (2011) · International Journal of Hypertension · doi:10.4061/2011/143471 · Cited by 40
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension
Shin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0013-2 · Cited by 40
Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes
Velasco, A., Siddiqui, M., Kreps, E., Kolakalapudi, P., Dudenbostel, T., Arora, G., Judd, E. K., Prabhu, S. D., Lloyd, S. G., Oparil, S., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.10965 · Cited by 39
Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea: a systematic review and meta-analysis
Shantha, G. P. S., & Pancholy, S. B. (2014) · Sleep And Breathing · doi:10.1007/s11325-014-0991-z · Cited by 38
Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Alfie, J., Aparicio, L. S., & D., W. (2011) · Reviews on Recent Clinical Trials · doi:10.2174/157488711795177912 · Cited by 37
Normotensive Blood Pressure in Pregnancy
Gennari‐Moser, C., Escher, G., Kramer, S., Dick, B., Eisele, N., Baumann, M. U., Raio, L., Frey, F. J., Surbek, D., & Mohaupt, M. G. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02320 · Cited by 37
Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis
Khurshid, K., Yabes, J. G., Weiss, P. M., Dharia, S. M., Brown, L. K., Unruh, M. L., & Jhamb, M. (2016) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6054 · Cited by 36
Influence of Lower Body Positive Pressure on Upper Airway Cross-Sectional Area in Drug-Resistant Hypertension
Friedman, O., Bradley, T. D., & Logan, A. G. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.203547 · Cited by 35
Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study
Rossi, G. P., Rossitto, G., Amar, L., Azizi, M., Riester, A., Reincke, M., Degenhart, C., Widimsky, J., Jr., Naruse, M., Deinum, J., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa108 · Cited by 38
Hypertension and Cardiac Failure in its Various Forms
Gaddam, K. K., Verma, A., Thompson, M., Amin, R. R., & Ventura, H. O. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.02.005 · Cited by 35
Self-citation
Refractory versus resistant hypertension: Novel distinctive phenotypes.
Dudenbostel, T., Siddiqui, M., Gharpure, N., & Calhoun, D. A. (2017) · PubMed · Cited by 34
Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan
Danaietash, P., Verweij, P., Wang, J., Dresser, G. K., Kantola, I. M., Lawrence, M. K., Narkiewicz, K., Schlaich, M. P., Bellet, M., & the PRECISION investigators (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14517 · Cited by 35
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
Volk, M. J., Bomback, A. S., & Klemmer, P. J. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0202-2 · Cited by 33
Refractory versus resistant hypertension
Siddiqui, M., & Calhoun, D. A. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000286 · Cited by 33
Salt, aldosterone and hypertension
Pimenta, E., Gordon, R. D., & Stowasser, M. (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2012.27 · Cited by 33
The Egyptian Hypertension Society
(2014) · The Egyptian Heart Journal · doi:10.1016/j.ehj.2014.03.001 · Cited by 33
Resistant hypertension and hyperaldosteronism
Gonzaga, C. C., & Calhoun, D. A. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0092-0 · Cited by 33
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO
Parthasarathy, H. K., Al-Hashmi, K., McMahon, A. D., Struthers, A. D., McInnes, G. T., Ford, I., Connell, J., & MacDonald, T. M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328332b79b · Cited by 32
A genome-wide association study identifies a novel candidate locus at the DLGAP1 gene with susceptibility to resistant hypertension in the Japanese population
Takahashi, Y., Yamazaki, K., Kamatani, Y., Kubo, M., Matsuda, K., & Asai, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-98144-z · Cited by 33
Association of treatment-resistant hypertension defined by home blood pressure monitoring with cardiovascular outcome
Narita, K., Hoshide, S., & Kario, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00757-4 · Cited by 31
Aprocitentan and the endothelin system in resistant hypertension
Clozel, M. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0010 · Cited by 31
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
Yugar‐Toledo, J. C., Modolo, R., de Faria, A. P., & Moreno, H. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s138599 · Cited by 32
Extracellular Fluid Volume Is an Independent Determinant of Uncontrolled and Resistant Hypertension in Chronic Kidney Disease: A NephroTest Cohort Study
Vidal‐Petiot, E., Metzger, M., Faucon, A., Boffa, J., Haymann, J., Thervet, É., Houillier, P., Géri, G., Stengel, B., Vrtovsnik, F., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.010278 · Cited by 30
Modulation of aldosterone levels by −344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension
Fontana, V., de Faria, A. P., Barbaro, N. R., Sabbatini, A. R., Modolo, R., Lacchini, R., & Moreno, H. (2013) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2013.12.001 · Cited by 30
Aldosterone, a vasculotoxic agent--novel functions for an old hormone
Ritz, E., & Tomaschitz, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp206 · Cited by 30
Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension
de Souza, F., Muxfeldt, E. S., Margallo, V. S., Cortez, A. F., Cavalcanti, A. H., & Salles, G. F. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001254 · Cited by 30
Resistant Hypertension: Concepts and Approach to Management
Sander, G. E., & Giles, T. D. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0226-7 · Cited by 29

Authors: Gaddam, K. K.
Affiliations: University of Alabama at Birmingham (US)
Corresponding author: Gaddam, Krishna K.
Venue: Archives of Internal Medicine
Publisher: American Medical Association (AMA)
Published: 2008-06-09
Volume: 168
Issue: 11
Pages: 1159
ISSN: 0003-9926 (ISSN-L)
DOI: 10.1001/archinte.168.11.1159
PMC: PMC2748247
OpenAlex: W2118344567
Cited by: 301
References: 32
Citations by year: 2026: 16 · 2025: 10 · 2024: 9 · 2023: 18 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 19 · 2017: 21 · 2016: 20 · 2015: 19 · 2014: 21 · 2013: 24 · 2012: 22
FWCI: 13.02
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Archives of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (HL-007457, HL077100, HL-075614, R01HL075614, P50HL077100, T32HL007457)
National Center for Research Resources (M01RR00032, M01RR000032)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: resistant hypertension, plasma aldosterone, aldosterone-renin ratio, plasma renin activity, brain natriuretic peptide, atrial natriuretic peptide, intravascular volume expansion, urinary cortisol, serum potassium, urinary sodium, sex differences, body mass index, target organ damage, aldosterone excess
MeSH terms: Aldosterone, Antihypertensive Agents, Drug Resistance, Female, Humans, Hydrocortisone, Hypertension, Male, Middle Aged, Atrial Natriuretic Factor, Potassium, Regression Analysis, Renin, Sex Factors, Sodium, Case-Control Studies, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of Resistant Hypertension<subtitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subtitle>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks